Alex Sparreboom

31.3k total citations · 3 hit papers
408 papers, 24.4k citations indexed

About

Alex Sparreboom is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Alex Sparreboom has authored 408 papers receiving a total of 24.4k indexed citations (citations by other indexed papers that have themselves been cited), including 310 papers in Oncology, 168 papers in Molecular Biology and 85 papers in Pharmacology. Recurrent topics in Alex Sparreboom's work include Drug Transport and Resistance Mechanisms (140 papers), Cancer Treatment and Pharmacology (119 papers) and Cancer therapeutics and mechanisms (111 papers). Alex Sparreboom is often cited by papers focused on Drug Transport and Resistance Mechanisms (140 papers), Cancer Treatment and Pharmacology (119 papers) and Cancer therapeutics and mechanisms (111 papers). Alex Sparreboom collaborates with scholars based in United States, Netherlands and Germany. Alex Sparreboom's co-authors include Jaap Verweij, William D. Figg, Kees Nooter, Ron H.J. Mathijssen, Walter J. Loos, Hans Gelderblom, Sharyn D. Baker, G. Stoter, Peter de Bruijn and Jos H. Beijnen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Nature Communications.

In The Last Decade

Alex Sparreboom

398 papers receiving 23.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cremophor EL

2001 1.4k citations Jaap Verweij, Kees Nooter et al. profile →
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1997 749 citations Alex Sparreboom et al. profile →
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

2001 626 citations Ron H.J. Mathijssen, Kees Nooter et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Sparreboom United States	86	14.2k	8.9k	3.3k	3.3k	2.7k	408	24.4k
Jan H.M. Schellens Netherlands	91	22.6k 1.6×	16.1k 1.8×	3.2k 1.0×	3.6k 1.1×	6.4k 2.3×	882	41.1k
Suresh V. Ambudkar United States	79	14.4k 1.0×	11.1k 1.2×	3.7k 1.1×	1.4k 0.4×	1.3k 0.5×	315	23.8k
Howard L. McLeod United States	81	10.1k 0.7×	9.6k 1.1×	2.6k 0.8×	6.6k 2.0×	2.6k 0.9×	481	26.6k
Olaf van Tellingen Netherlands	64	10.0k 0.7×	5.3k 0.6×	3.8k 1.1×	1.8k 0.6×	1.4k 0.5×	238	16.1k
Alfred H. Schinkel Netherlands	88	22.2k 1.6×	8.7k 1.0×	10.6k 3.2×	4.0k 1.2×	1.5k 0.6×	297	30.8k
William D. Figg United States	86	10.0k 0.7×	11.5k 1.3×	1.0k 0.3×	1.3k 0.4×	4.4k 1.6×	604	25.3k
Mark J. Ratain United States	74	10.2k 0.7×	9.1k 1.0×	2.1k 0.6×	2.8k 0.9×	4.3k 1.6×	532	23.0k
Hilde Rosing Netherlands	56	6.7k 0.5×	4.6k 0.5×	1.5k 0.5×	1.6k 0.5×	1.5k 0.5×	422	13.3k
Takashi Tsuruo Japan	89	12.4k 0.9×	16.6k 1.9×	1.9k 0.6×	1.1k 0.3×	1.2k 0.5×	446	27.7k
Ron H.J. Mathijssen Netherlands	66	7.2k 0.5×	5.1k 0.6×	1.4k 0.4×	1.7k 0.5×	3.5k 1.3×	453	14.3k

Countries citing papers authored by Alex Sparreboom

Since Specialization

Citations

This map shows the geographic impact of Alex Sparreboom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Sparreboom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Sparreboom more than expected).

Fields of papers citing papers by Alex Sparreboom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Sparreboom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Sparreboom. The network helps show where Alex Sparreboom may publish in the future.

Co-authorship network of co-authors of Alex Sparreboom

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Sparreboom. A scholar is included among the top collaborators of Alex Sparreboom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Sparreboom. Alex Sparreboom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Yang, Kevin M. Huang, Eman Ahmed, et al.. (2025). OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility. Cancer Research Communications. 5(3). 497–511.

Talebi, Zahra, et al.. (2020). Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics. 12(9). 856–856. 31 indexed citations

Atrafi, Florence, Ruben A.G. van Eerden, Esther Oomen‐de Hoop, et al.. (2020). Intratumoral Comparison of Nanoparticle Entrapped Docetaxel (CPC634) with Conventional Docetaxel in Patients with Solid Tumors. Clinical Cancer Research. 26(14). 3537–3545. 45 indexed citations

Li, Jing, Jianmei Wu, Xun Bao, et al.. (2017). Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients Using an IVIVE–PBPK Modeling Approach. Clinical Cancer Research. 23(24). 7454–7466. 45 indexed citations

Hu, Shuiying, et al.. (2016). ABCC4 Is a Determinant of Cytarabine‐Induced Cytotoxicity and Myelosuppression. Clinical and Translational Science. 9(1). 51–59. 27 indexed citations

Sprowl, Jason A., Cynthia S. Lancaster, Navjotsingh Pabla, et al.. (2014). Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53. Clinical Cancer Research. 20(15). 4026–4035. 61 indexed citations

Nieuweboer, Annemieke J.M., Shuiying Hu, Chunshan Gui, et al.. (2014). Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel. Cancer Research. 74(11). 3137–3145. 47 indexed citations

Graan, Anne‐Joy M. de, Laure Elens, Jason A. Sprowl, et al.. (2013). CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research. 19(12). 3316–3324. 91 indexed citations

Zimmerman, Eric I., Shuiying Hu, Alice A. Gibson, et al.. (2013). Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide. Clinical Cancer Research. 19(6). 1458–1466. 131 indexed citations

10.

Sprowl, Jason A., Vanesa Gregorc, Chiara Lazzari, et al.. (2012). Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy. Clinical Pharmacology & Therapeutics. 91(6). 1022–1026. 29 indexed citations

11.

Eechoute, Karel, Martin N. Fransson, Floris A. de Jong, et al.. (2012). A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients. Clinical Cancer Research. 18(20). 5780–5787. 87 indexed citations

12.

Hu, Chaoxin, Cynthia S. Lancaster, Zhili Zuo, et al.. (2012). Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Molecular Cancer Therapeutics. 11(4). 921–929. 54 indexed citations

13.

Bol, Jessica M. van der, Ron H.J. Mathijssen, Geert-Jan Creemers, et al.. (2010). A CYP3A4 Phenotype–Based Dosing Algorithm for Individualized Treatment of Irinotecan. Clinical Cancer Research. 16(2). 736–742. 50 indexed citations

14.

Franke, Ryan M., Cynthia S. Lancaster, Kelly K. Filipski, et al.. (2010). Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N -Acetyl-β-D-Glucosaminidase. Clinical Cancer Research. 16(16). 4198–4206. 70 indexed citations

15.

Hu, Shuiying, Zhaoyuan Chen, Ryan M. Franke, et al.. (2009). Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters. Clinical Cancer Research. 15(19). 6062–6069. 129 indexed citations

16.

Hamada, Akinobu, Tristan M. Sissung, Douglas K. Price, et al.. (2008). Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer. Clinical Cancer Research. 14(11). 3312–3318. 153 indexed citations

17.

Kroetz, Deanna L., H. L. McLeod, Lena E. Friberg, et al.. (2006). Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein. Clinical Pharmacology & Therapeutics. 81(1). 42–49. 131 indexed citations

18.

Smith, Nicola F., Milin Acharya, William D. Figg, & Alex Sparreboom. (2005). Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Research. 65. 970–970. 1 indexed citations

19.

Burger, Herman, Hans van Tol, Mariël Brok, et al.. (2005). Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biology & Therapy. 4(7). 747–752. 159 indexed citations

20.

Mathijssen, Ron H.J., Sharon Marsh, Mats O. Karlsson, et al.. (2003). Irinotecan pathway genotype analysis to predict pharmacokinetics.. PubMed. 9(9). 3246–53. 209 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact